CBT Cabot (CBT) Insider Trading, Ownership & Congress Trades
Materials · Miscellaneous chemical products · CIK 0000016040
Form 144 · 3
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
210
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $12.6M priced
What the filings say about CBT
Insiders, 180 days
-$19.6M net sold
1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$19.6M
3 notices
Cabot insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, CABOT CORP insiders sold a net $19.6M of stock across 64 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Aug 24, 2026.
- The trade is 33.4% of the 404,134 shares held after it.
- No other insider sold within 30 days.
- 210 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Keohane Sean D sold about $11.5M of CBT on Aug 28, 2026, the largest insider sale at the company on our record; 210 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Aug 7, 2026.
- The trade is 1.0% of the 288,873 shares held after it.
- No other insider sold within 30 days.
- 210 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Keohane Sean D sold about $237.6K of CBT on Aug 24, 2026; 210 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Aug 14, 2025.
- The trade is 22.7% of the 404,134 shares held after it.
- No other insider sold within 30 days.
- 210 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Keohane Sean D sold about $7.9M of CBT on Aug 7, 2026, the largest insider sale at the company on our record; 210 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Sep 3, 2024.
- The trade is 0.7% of the 361,518 shares held after it.
- No other insider sold within 30 days.
- 210 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Keohane Sean D sold about $188.6K of CBT on Aug 14, 2025; 210 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (7 sales), the last on Sep 3, 2024.
- The trade is 21.8% of the 369,195 shares held after it.
- No other insider sold within 30 days.
- 210 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Keohane Sean D sold about $6.4M of CBT on Aug 14, 2025, the largest insider sale at the company on our record; 210 funds added in the latest 13F quarter.64 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$19.6M over 180 days
-$19.6M over 90 days
below 96% of Materials
Congress
no House purchase disclosed in the last 12 months
Funds
210 funds bought in last quarter
more than 69% of Materials
Revenue
-7.0% year over year
below 77% of Materials
Margin
8.9% net margin
more than 79% of Materials
Buybacks
$101.0M repurchased, FY to 2026-06-30
more than 63% of Materials
Short interest
8.7% of the float short (float per yahoo 2026-10-26) · 10.1 days to cover · settled 2026-09-30
more than 81% of Materials
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CBT
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+6.0%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CBT: institutional holders (13F)
13F holdings, latest reported quarter
6,973,153 sh
$633.3M
3,345,689 sh
$303.9M
3,076,935 sh
$279.4M
2,768,176 sh
$251.4M
2,416,471 sh
$219.5M
Congress trades in CBT
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CBT planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Keohane Sean D
Filed 2026-08-28
$11.5M
Keohane Sean D
Filed 2026-08-24
$237.6K
Keohane Sean D
Filed 2026-08-07
$7.9M
CBT mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Pear tree polaris small cap fund
$2.4M position · as of 2026-06-30
2.4%
Euclidean Fundamental Value ETF
$2.6M position · as of 2026-06-30
2.0%
Select Chemicals Portfolio
$8.5M position · as of 2026-05-31
1.9%
BALLAST SMALL/MID CAP ETF
$3.3M position · as of 2026-06-30
1.9%
ProShares S&P MidCap 400 Dividend Aristocrats ETF
$30.3M position · as of 2026-05-31
1.8%
Undiscovered Managers Behavioral Value Fund
$147.1M position · as of 2026-06-30
1.6%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Sean D. Keohane
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$9.3M
$1.3M
$2.4M
+135%
+34%
2024
$9.6M
$26.1M
$2.7M
+239%
+56%
2023
$7.8M
$8.1M
$2.2M
+106%
+35%
2022
$7.9M
$17.2M
$2.3M
+86%
+17%
2021
$8.2M
$17.1M
$2.3M
+43%
+36%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $19.6M sold by insiders over 180 days, 210 funds added last quarter, $19.6M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
CBT financials
Revenue growth
-7.0%
XBRL, annual
Net margin
8.9%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.6B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM CBT
| FY Sep 2025 | $3.7B |
| FY Sep 2024 | $4.0B |
| FY Sep 2023 | $3.9B |
| FY Sep 2022 | $4.3B |
| FY Sep 2021 | $3.4B |
| Jun 2026 | $982.0M |
| Mar 2026 | $904.0M |
| Dec 2025 | $849.0M |
| Sep 2025 | $899.0M |
| Jun 2025 | $923.0M |
| Mar 2025 | $936.0M |
| Dec 2024 | $955.0M |
| Sep 2024 | $1.0B |
At each fiscal year end
Single quarter
Net margin, TTM
+5.2%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM CBT
| FY Sep 2025 | +8.9% |
| FY Sep 2024 | +9.5% |
| FY Sep 2023 | +11.3% |
| FY Sep 2022 | +4.8% |
| FY Sep 2021 | +7.3% |
| Jun 2026 | +0.6% |
| Mar 2026 | +7.5% |
| Dec 2025 | +8.6% |
| Sep 2025 | +4.8% |
| Jun 2025 | +10.9% |
| Mar 2025 | +10.0% |
| Dec 2024 | +9.7% |
| Sep 2024 | +13.7% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$281.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM CBT
| FY Sep 2025 | $391.0M |
| FY Sep 2024 | $451.0M |
| FY Sep 2023 | $351.0M |
| FY Sep 2022 | -$111.0M |
| FY Sep 2021 | $62.0M |
| Jun 2026 | $37.0M |
| Mar 2026 | $32.0M |
| Dec 2025 | $57.0M |
| Sep 2025 | $155.0M |
| Jun 2025 | $188.0M |
| Mar 2025 | $1.0M |
| Dec 2024 | $47.0M |
| Sep 2024 | $112.0M |
At each fiscal year end
Single quarter
Debt to equity
0.68x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity CBT
| FY Sep 2025 | 0.72x |
| FY Sep 2024 | 0.77x |
| FY Sep 2023 | 0.87x |
| FY Sep 2022 | 1.22x |
| FY Sep 2021 | 1.15x |
| Jun 2026 | 0.68x |
| Mar 2026 | 0.72x |
| Dec 2025 | 0.71x |
| Sep 2025 | 0.72x |
| Jun 2025 | 0.72x |
| Mar 2025 | 0.77x |
| Dec 2024 | 0.80x |
| Sep 2024 | 0.77x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.46x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt CBT
| FY Sep 2025 | 0.60x |
| FY Sep 2024 | 0.63x |
| FY Sep 2023 | 0.54x |
| FY Sep 2022 | 0.09x |
| FY Sep 2021 | 0.24x |
| Jun 2026 | 0.46x |
| Mar 2026 | 0.60x |
| Dec 2025 | 0.60x |
| Sep 2025 | 0.60x |
| Jun 2025 | 0.58x |
| Mar 2025 | 0.55x |
| Dec 2024 | 0.65x |
| Sep 2024 | 0.63x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+12.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity CBT
| FY Sep 2025 | +22.3% |
| FY Sep 2024 | +28.3% |
| FY Sep 2023 | +41.2% |
| FY Sep 2022 | +22.7% |
| FY Sep 2021 | +30.5% |
| Jun 2026 | +12.1% |
| Mar 2026 | +19.0% |
| Dec 2025 | +21.1% |
| Sep 2025 | +22.3% |
| Jun 2025 | +29.4% |
| Mar 2025 | +31.0% |
| Dec 2024 | +31.4% |
| Sep 2024 | +28.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+4.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets CBT
| FY Sep 2025 | +8.8% |
| FY Sep 2024 | +10.4% |
| FY Sep 2023 | +12.5% |
| FY Sep 2022 | +6.1% |
| FY Sep 2021 | +8.2% |
| Jun 2026 | +4.9% |
| Mar 2026 | +7.4% |
| Dec 2025 | +8.4% |
| Sep 2025 | +8.8% |
| Jun 2025 | +11.5% |
| Mar 2025 | +11.7% |
| Dec 2024 | +11.5% |
| Sep 2024 | +10.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+11.0%
operating income after a 46.2% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital CBT
| FY Sep 2025 | +17.2% |
| FY Sep 2024 | +22.0% |
| FY Sep 2023 | n/a |
| FY Sep 2022 | +14.8% |
| FY Sep 2021 | +18.1% |
| Jun 2026 | +11.0% |
| Mar 2026 | +14.9% |
| Dec 2025 | +16.1% |
| Sep 2025 | +17.2% |
| Jun 2025 | +21.4% |
| Mar 2025 | +22.2% |
| Dec 2024 | +22.6% |
| Sep 2024 | +22.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+16.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed CBT
| FY Sep 2025 | +21.3% |
| FY Sep 2024 | +21.4% |
| FY Sep 2023 | +20.2% |
| FY Sep 2022 | +17.0% |
| FY Sep 2021 | +20.6% |
| Jun 2026 | +16.6% |
| Mar 2026 | +19.4% |
| Dec 2025 | +20.6% |
| Sep 2025 | +21.3% |
| Jun 2025 | +21.3% |
| Mar 2025 | +21.9% |
| Dec 2024 | +22.0% |
| Sep 2024 | +21.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
20.79x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing CBT
| FY Sep 2025 | 12.63x |
| FY Sep 2024 | 16.61x |
| FY Sep 2023 | 8.96x |
| FY Sep 2022 | 17.80x |
| FY Sep 2021 | 11.55x |
| Jun 2026 | 25.51x |
| Mar 2026 | 14.21x |
| Dec 2025 | 11.59x |
| Sep 2025 | 12.63x |
| Jun 2025 | 9.82x |
| Mar 2025 | 10.77x |
| Dec 2024 | 12.14x |
| Sep 2024 | 16.61x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$4.7B
market value at close 2026-10-27 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value CBT
| FY Sep 2025 | $4.9B |
| FY Sep 2024 | $7.0B |
| FY Sep 2023 | $4.7B |
| FY Sep 2022 | $4.5B |
| FY Sep 2021 | $3.8B |
| Jun 2026 | $5.5B |
| Mar 2026 | $4.8B |
| Dec 2025 | $4.4B |
| Sep 2025 | $4.9B |
| Jun 2025 | $4.9B |
| Mar 2025 | $5.4B |
| Dec 2024 | $5.9B |
| Sep 2024 | $7.0B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+7.4%
TTM free cash flow over market value at close 2026-10-27
FCF yield CBT
| FY Sep 2025 | +9.7% |
| FY Sep 2024 | +7.4% |
| FY Sep 2023 | +9.1% |
| FY Sep 2022 | -3.1% |
| FY Sep 2021 | +2.2% |
| Jun 2026 | +6.0% |
| Mar 2026 | +11.0% |
| Dec 2025 | +11.4% |
| Sep 2025 | +9.7% |
| Jun 2025 | +8.6% |
| Mar 2025 | +7.0% |
| Dec 2024 | +9.0% |
| Sep 2024 | +7.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -53%, PEG needs growth
PEG, trailing CBT
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | 0.08x |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-09 | 2024-09 | 2023-09 | 2022-09 | |
|---|---|---|---|---|
| Revenue | $3.7B | $4.0B | $3.9B | $4.3B |
| Gross profit | $940.0M | $960.0M | $839.0M | $885.0M |
| Operating income | $621.0M | $614.0M | $526.0M | $389.0M |
| Net income | $331.0M | $380.0M | $445.0M | $209.0M |
| EPS (diluted) | 6.02 | 6.72 | 7.73 | 3.62 |
| Operating cash flow | $665.0M | $692.0M | $595.0M | $100.0M |
| Cash | $258.0M | $223.0M | $238.0M | $206.0M |
| Long-term debt | $856.0M | $1.1B | $1.1B | $1.1B |
| Buybacks | $168.0M | $172.0M | $98.0M | $53.0M |
| Dividends paid | $96.0M | $93.0M | $88.0M | $84.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
CBT Stock Sonar score 6/7 axes
Find similar shapesCompareCBT ranks highest on profitability (67th percentile) and financial health (67th), and lowest on insider conviction (2nd), among Materials peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
CBT filings, in plain words
Are Cabot insiders buying or selling CBT?
In the 180 days to 2026-10-28, Cabot insiders were net sellers, a net $19.6M across purchases and sales reported on Form 4, by 1 seller.
Are there planned insider sales of CBT?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $19.6M of stock; the latest, by Keohane Sean D, was filed 2026-08-28.
Read the full summary
In the 180 days to 2026-10-28, Cabot insiders were net sellers of CBT, a net $19.6M across purchases and sales reported on Form 4 by 1 seller. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $19.6M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
